Imen Halloul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Imen Halloul has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
K. Ach
Service d’endocrinologie–diabétologie, CHU Farhat-Hached, Sousse, Tunisie
5 shared publicationsA. Ben Abdelkerim
Service d’endocrinologie–diabétologie, CHU Farhat Hached, Sousse, Tunisie
4 shared publicationsA. Maaroufi
Service d’endocrinologie–diabétologie, CHU Farhat-Hached, Sousse, Tunisie
4 shared publicationsG. Saad
Service d’endocrinologie–diabétologie, CHU Farhat-Hached, Sousse, Tunisie
4 shared publications- Ghada Saad
Faculty of Medicine of Sousse, University of Sousse, Sousse 4002, Tunisia
4 shared publications M. Chaieb
Service d’endocrinologie–diabétologie, CHU Farhat-Hached, Sousse, Tunisie
4 shared publications
Latest Publications
- Open Access
- 11 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (8) , 1143
Cerebral Metastasis in a Fatal Adrenocortical Carcinoma: A Rare Presentation of an Aggressive Tumor
Adrenocortical carcinomas (ACCs) are rare, aggressive tumors often discovered incidentally. These malignancies may present with abnormal hormone secretion or, as in some cases, as non-functioning masses causing discomfort. We present a case of brain metastasis in a patient with a giant ACC. A 50-year-old man presented with headache and dizziness. A computed tomography (CT) scan showed an intracranial lesion within the parenchyma measuring 73*60*46 mm with left internal temporal involvement, abundant vasogenic edema and compressing the lateral left ventricle. Further imaging investigations identified a large necrotic tissue mass measuring 15 cm, located on both sides of the right diaphragmatic dome, in the middle posterior region. Hormonal workup was conducted and excluded a functional adrenal tumor. A CT-guided biopsy was performed, confirming ACC. Despite medical management, the patient’s condition deteriorated rapidly, with the cerebral metastasis proving fatal. This case underscores the challenges posed by advanced ACC, particularly when associated with atypical metastatic sites. Giant ACC, though rare, presents significant diagnostic and therapeutic challenges. Surgical excision with appropriate oncologic management can lead to favorable outcomes. This report contributes to the limited literature on cerebral metastases in ACC, aiming to enhance awareness among clinicians managing this rare entity.
- 11 April 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (8) , 1143
Open AccessCerebral Metastasis in a Fatal Adrenocortical Carcinoma: A Rare Presentation of an Aggressive Tumor
Adrenocortical carcinomas (ACCs) are rare, aggressive tumors often discovered incidentally. These malignancies may present with abnormal hormone secretion or, as in some cases, as non-functioning masses causing discomfort. We present a case of brain metastasis in a patient with a giant ACC. A 50-year-old man presented with headache and dizziness. A computed tomography (CT) scan showed an intracranial lesion within the parenchyma measuring 73*60*46 mm with left internal temporal involvement, abundant vasogenic edema and compressing the lateral left ventricle. Further imaging investigations identified a large necrotic tissue mass measuring 15 cm, located on both sides of the right diaphragmatic dome, in the middle posterior region. Hormonal workup was conducted and excluded a functional adrenal tumor. A CT-guided biopsy was performed, confirming ACC. Despite medical management, the patient’s condition deteriorated rapidly, with the cerebral metastasis proving fatal. This case underscores the challenges posed by advanced ACC, particularly when associated with atypical metastatic sites. Giant ACC, though rare, presents significant diagnostic and therapeutic challenges. Surgical excision with appropriate oncologic management can lead to favorable outcomes. This report contributes to the limited literature on cerebral metastases in ACC, aiming to enhance awareness among clinicians managing this rare entity.
- Open Access
- 15 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2334
A Predictive Score Incorporating Clinical, Radiologic, and Hormonal Parameters to Discriminate Lymphocytic Hypophysitis from Non-Functioning Pituitary Macroadenomas
Background/Objectives: Non-functional pituitary macroadenomas (NFPMA) are uncommon pituitary lesions that do not cause hormonal hypersecretion and are most often discovered at the macroadenoma stage. Consequently, they are more challenging to diagnose, often mimicking other non-secreting sellar masses, among which hypophysitis should be carefully considered. This study aimed to differentiate between non-functioning pituitary macroadenomas (NFPMA) and hypophysitis, two distinct sellar pathologies with overlapping MRI features, by developing a diagnostic score based on clinical, biological, and radiological criteria. Methods: We conducted a prospective study, including 56 patients with NFPMA and 16 patients with hypophysitis primarily of the lymphocytic subtype. A total of 31 clinical, biological, and radiological variables were analyzed using univariate and multivariate statistical methods to identify significant predictors and to establish a diagnostic score. Results: Nine significant criteria were identified: female sex, headaches, visual disturbances, corticotropic insufficiency, pituitary volume ≤ 7 cm3, loss of the posterior pituitary bright spot, cavernous sinus invasion, optic pathway compression, and pituitary stalk thickening. The established score demonstrated significant performance in predicting the diagnosis of hypophysitis (p < 0.001; Area Under the Curve = 0.967; 95% CI = 0.926–1). The sensitivity and specificity of this score were 93.8% and 87.5%, respectively, using a threshold ≥0.5. The median score was −2 (interquartile range = [−3.5; 0.5]), with extremes ranging from −6.5 to 9. Among these, pituitary stalk thickening emerged as a key diagnostic indicator. Conclusions: This simple and effective multi-parametric score enables rapid and accurate differentiation of hypophysitis from NFPMA, helping to avoid unnecessary surgical interventions and to improve the management of pituitary insufficiencies and may be especially valuable in settings when biopsy is unavailable or risky.
- 15 September 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (18) , 2334
Open AccessA Predictive Score Incorporating Clinical, Radiologic, and Hormonal Parameters to Discriminate Lymphocytic Hypophysitis from Non-Functioning Pituitary Macroadenomas
Background/Objectives: Non-functional pituitary macroadenomas (NFPMA) are uncommon pituitary lesions that do not cause hormonal hypersecretion and are most often discovered at the macroadenoma stage. Consequently, they are more challenging to diagnose, often mimicking other non-secreting sellar masses, among which hypophysitis should be carefully considered. This study aimed to differentiate between non-functioning pituitary macroadenomas (NFPMA) and hypophysitis, two distinct sellar pathologies with overlapping MRI features, by developing a diagnostic score based on clinical, biological, and radiological criteria. Methods: We conducted a prospective study, including 56 patients with NFPMA and 16 patients with hypophysitis primarily of the lymphocytic subtype. A total of 31 clinical, biological, and radiological variables were analyzed using univariate and multivariate statistical methods to identify significant predictors and to establish a diagnostic score. Results: Nine significant criteria were identified: female sex, headaches, visual disturbances, corticotropic insufficiency, pituitary volume ≤ 7 cm3, loss of the posterior pituitary bright spot, cavernous sinus invasion, optic pathway compression, and pituitary stalk thickening. The established score demonstrated significant performance in predicting the diagnosis of hypophysitis (p < 0.001; Area Under the Curve = 0.967; 95% CI = 0.926–1). The sensitivity and specificity of this score were 93.8% and 87.5%, respectively, using a threshold ≥0.5. The median score was −2 (interquartile range = [−3.5; 0.5]), with extremes ranging from −6.5 to 9. Among these, pituitary stalk thickening emerged as a key diagnostic indicator. Conclusions: This simple and effective multi-parametric score enables rapid and accurate differentiation of hypophysitis from NFPMA, helping to avoid unnecessary surgical interventions and to improve the management of pituitary insufficiencies and may be especially valuable in settings when biopsy is unavailable or risky.
- Open Access
Redefining the Diagnostic Approach to Adrenal Insufficiency: Re-Assessment of Baseline and Cortisol Increment Cut-Offs with the 1 µg Synacthen Test
Background and Objectives: Adrenal insufficiency (AI) is an endocrine disorder characterized by inadequate cortisol production, leading to non-specific symptoms that delay diagnosis. The Low Dose Synacthen Test (LDST) is commonly used to evaluate adrenal function, but traditional cortisol cut-offs may not accurately reflect adrenal function in all patients. This study aims to identify baseline cortisol cut-offs to accurately rule in and out AI, reassess the value of cortisol increment during LDST, and evaluate the accuracy of 30 and 60 min cortisol measurements in diagnosing AI. Materials and Methods: We conducted a cross-sectional analysis of patients who underwent LDST at Farhat Hached University Hospital. Diagnostic accuracy of baseline cortisol levels and cortisol increment was assessed using ROC curve analysis to determine optimal cut-offs for predicting LDST outcomes. Results: Among 163 patients (mean age 42.9 years, 63% female), baseline cortisol ≤ 5.35 μg/dL had 100% specificity but 41.5% sensitivity for LDST failure. Conversely, baseline cortisol ≥ 12.4 μg/dL had 100% sensitivity with 45.9% specificity. Single measurements at 30 and 60 min correctly classified 92.64% and 93.87% of cases, respectively. ROC analysis of 30 and 60 min cortisol increments showed high diagnostic accuracy (AUC 0.923 and 0.914, respectively). The optimal cortisol increment cut-off was 6.35 μg/dL for ruling in AI (99% specificity). Conclusions: We propose a novel AI diagnostic algorithm based on a single 30 min cortisol measurement, complemented by revised baseline cortisol cut-offs and cortisol increment as additional criteria. This approach may enhance diagnostic accuracy and minimize unnecessary testing, warranting further clinical validation.
Open AccessRedefining the Diagnostic Approach to Adrenal Insufficiency: Re-Assessment of Baseline and Cortisol Increment Cut-Offs with the 1 µg Synacthen Test
Background and Objectives: Adrenal insufficiency (AI) is an endocrine disorder characterized by inadequate cortisol production, leading to non-specific symptoms that delay diagnosis. The Low Dose Synacthen Test (LDST) is commonly used to evaluate adrenal function, but traditional cortisol cut-offs may not accurately reflect adrenal function in all patients. This study aims to identify baseline cortisol cut-offs to accurately rule in and out AI, reassess the value of cortisol increment during LDST, and evaluate the accuracy of 30 and 60 min cortisol measurements in diagnosing AI. Materials and Methods: We conducted a cross-sectional analysis of patients who underwent LDST at Farhat Hached University Hospital. Diagnostic accuracy of baseline cortisol levels and cortisol increment was assessed using ROC curve analysis to determine optimal cut-offs for predicting LDST outcomes. Results: Among 163 patients (mean age 42.9 years, 63% female), baseline cortisol ≤ 5.35 μg/dL had 100% specificity but 41.5% sensitivity for LDST failure. Conversely, baseline cortisol ≥ 12.4 μg/dL had 100% sensitivity with 45.9% specificity. Single measurements at 30 and 60 min correctly classified 92.64% and 93.87% of cases, respectively. ROC analysis of 30 and 60 min cortisol increments showed high diagnostic accuracy (AUC 0.923 and 0.914, respectively). The optimal cortisol increment cut-off was 6.35 μg/dL for ruling in AI (99% specificity). Conclusions: We propose a novel AI diagnostic algorithm based on a single 30 min cortisol measurement, complemented by revised baseline cortisol cut-offs and cortisol increment as additional criteria. This approach may enhance diagnostic accuracy and minimize unnecessary testing, warranting further clinical validation.
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 484
Intrication du déséquilibre chronique du diabète dans la majoration du risque de fibrose hépatique
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 484
Intrication du déséquilibre chronique du diabète dans la majoration du risque de fibrose hépatique
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 478
Évaluation des acquis concernant l’éducation thérapeutique de l’insulinothérapie chez les patients diabétiques de type 2
- 24 September 2021
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 82 (5) , 478
Évaluation des acquis concernant l’éducation thérapeutique de l’insulinothérapie chez les patients diabétiques de type 2
- Open Access
- 1 January 2021
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 38 (394)
Association of an empty sella and grave's disease in a patient with acromegaly: a case report
Acromegaly is, in most cases, caused by growth hormone secreting pituitary adenomas. Those patients often develop different pathologies of the thyroid gland, however, the occurrence of Grave's disease is quite a rare situation. We report a case of a 64-year-old female patient who presented with signs of hyperthyroidism and imbalance of her diabetes mellitus. On physical examination, she had facial features of acromegaly. Biochemical testing confirmed the suspicion of acromegaly and Grave's disease, with an elevated insulin-like growth factor-1 and a suppressed thyroid stimulation hormone with positive TSH-receptor antibodies. A pituitary Magnetic Resonance Imaging was performed, revealing a macro-adenoma and an empty sella. The patient successfully underwent a transsphenoidal surgery and obtained a remission of her hyperthyroidism under anti-thyroid drugs.
- 1 January 2021
- Published by Pan African Medical Journal in Pan African Medical Journal
- Vol. 38 (394)
Open AccessAssociation of an empty sella and grave's disease in a patient with acromegaly: a case report
Acromegaly is, in most cases, caused by growth hormone secreting pituitary adenomas. Those patients often develop different pathologies of the thyroid gland, however, the occurrence of Grave's disease is quite a rare situation. We report a case of a 64-year-old female patient who presented with signs of hyperthyroidism and imbalance of her diabetes mellitus. On physical examination, she had facial features of acromegaly. Biochemical testing confirmed the suspicion of acromegaly and Grave's disease, with an elevated insulin-like growth factor-1 and a suppressed thyroid stimulation hormone with positive TSH-receptor antibodies. A pituitary Magnetic Resonance Imaging was performed, revealing a macro-adenoma and an empty sella. The patient successfully underwent a transsphenoidal surgery and obtained a remission of her hyperthyroidism under anti-thyroid drugs.
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 413
Diabète type 1 chez des patients de plus de 50 ans : caractéristiques cliniques et biologiques
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 413
Diabète type 1 chez des patients de plus de 50 ans : caractéristiques cliniques et biologiques
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 357
Hyperaldostéronisme primaire : profil clinico-hormonal, thérapeutique et évolutif de 18 cas
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 357
Hyperaldostéronisme primaire : profil clinico-hormonal, thérapeutique et évolutif de 18 cas
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 398
Carcinome papillaire de la thyroïde à révélation inhabituelle, à propos d’un cas
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 398
Carcinome papillaire de la thyroïde à révélation inhabituelle, à propos d’un cas
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 285-286
Hypokaliémie sévère révélant une maladie de Cushing
- 30 September 2020
- Published by Elsevier in Annales d'Endocrinologie
- Vol. 81 (4) , 285-286
Hypokaliémie sévère révélant une maladie de Cushing